<DOC>
	<DOCNO>NCT01502371</DOCNO>
	<brief_summary>The primary objective study demonstrate dose-related efficacy , evaluate morning ( AM ) lung function end dose interval ( AM pre-dose percent predict forced expiratory volume one second [ FEV1 ] ) across 12 week treatment , three dos ( 50 mcg , 100 mcg , 200 mcg ) Mometasone Furoate ( MF ) Metered Dose Inhaler ( MDI ) twice day ( BID ) compare Placebo child 5 11 year age , inclusive , persistent asthma . The primary hypothesis study least one dose MF MDI BID increase lung function , define significant increase percent predict FEV1 , compare Placebo .</brief_summary>
	<brief_title>A Study Mometasone Furoate Metered Dose Inhaler Children With Persistent Asthma ( P04223 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Diagnosis asthma least 6 month duration . Using Inhaled corticosteroid ( ICS ) , either alone combination longacting beta2 agonist ( LABA ) , least 12 week prior Screening Visit must stable asthma regimen least 2 week prior Screening Visit , must use oral glucocorticosteroids within 30 day Screening Visit . Treated emergency room severe asthma exacerbation require systemic glucocorticosteroid treatment , hospitalization management airway obstruction within 3 month prior Screening Visit . History ventilator support respiratory failure secondary asthma . Upper low respiratory tract infection ( viral bacterial ) within 2 week prior Screening Baseline Visits . History clinically significant renal , hepatic , cardiovascular , metabolic , neurologic , hematologic , ophthalmologic , respiratory , gastrointestinal , cerebrovascular , significant medical illness disorder , judgment investigator , could interfere study require treatment might interfere study . Specific example include limited insulindependent diabetes , hypertension , active hepatitis , cardiovascular disease include hypertension , condition may interfere respiratory function , bronchiectasis , cystic fibrosis . Other condition well control stable prohibit participation deem appropriate per investigator 's judgment . Inability correctly use oral MDI DPI . Participation study another investigational site . Participation different investigational study site time frame study . Randomization study . Direct association either administration study study staff .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Children</keyword>
	<keyword>Persistent</keyword>
</DOC>